Vivani Medical Strengthens Director Compensation with Annual Stock Option Grant

Rhea-AI Filing Summary

Director Daniel Bradbury reported two key transactions in Vivani Medical (VANI) stock options:

• Acquired 35,135 non-qualified stock options on June 24, 2025, with exercise price of $1.27. These options vest fully on either the first anniversary or next annual stockholder meeting, whichever comes first. This was part of the annual director compensation policy.
• Correction to previous grant from January 1, 2025: Total options adjusted down from 50,059 to 49,822 (reduction of 237) due to clerical error. These options have a $1.16 exercise price and vest quarterly.

The transactions reflect standard board compensation practices and administrative corrections rather than open market trading activity. All holdings are directly owned, with no indirect beneficial ownership reported.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider BRADBURY DANIEL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right to buy)	35,135	$1.27	$45K
Disposition	Non-Qualified Stock Option (right to buy)	237	$1.16	$274.92

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 35,135 shares (Direct)

Footnotes (1)

1. Annual grant awarded pursuant to the Issuer's Non-Employee Director Compensation Policy. The option vests in total on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to continued service through such date. Reflects an adjustment to a previously reported amount grant on 01/01/2025 from 50,059 to 49,822 due to a clerical error. The option will vest one-fourth at the end of each calendar quarter following the grant date, subject to continued service through each such date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BRADBURY DANIEL

(Last) (First) (Middle)

C/O VIVANI MEDICAL, INC.

1350 S. LOOP ROAD

(Street)

ALAMEDA CA 94502

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vivani Medical, Inc. [ VANI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$1.27	06/24/2025		A		35,135		(1)(2)	06/23/2035	Common Stock	35,135(2)	$1.27(2)	35,135(2)	D
Non-Qualified Stock Option (right to buy)	$1.16	01/01/2025		D(3)			237(3)	(4)	12/31/2034	Common Stock	237(3)	$1.16	49,822(3)	D

Explanation of Responses:

1. Annual grant awarded pursuant to the Issuer's Non-Employee Director Compensation Policy.

2. The option vests in total on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to continued service through such date.

3. Reflects an adjustment to a previously reported amount grant on 01/01/2025 from 50,059 to 49,822 due to a clerical error.

4. The option will vest one-fourth at the end of each calendar quarter following the grant date, subject to continued service through each such date.

Remarks:

Exhibit 24 Power of Attorney

	/s/ Adam Mendelsohn, Attorney-in-fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did VANI director Daniel Bradbury receive on June 24, 2025?

Daniel Bradbury received 35,135 non-qualified stock options with an exercise price of $1.27 on June 24, 2025. These options were granted as part of VANI's annual Non-Employee Director Compensation Policy and will vest fully on either the first grant anniversary or the next annual stockholder meeting, whichever comes first.

When do Daniel Bradbury's June 2025 VANI stock options expire?

The non-qualified stock options granted to Daniel Bradbury on June 24, 2025, expire on June 23, 2035, giving them a 10-year term from the grant date.

What was the correction made to Bradbury's January 2025 VANI stock option grant?

The Form 4 disclosed a correction to Bradbury's January 1, 2025 stock option grant, adjusting the previously reported amount from 50,059 to 49,822 options (a reduction of 237 options) due to a clerical error. These options have an exercise price of $1.16.

What is the vesting schedule for VANI director Bradbury's January 2025 stock options?

The January 2025 stock options vest in four equal installments, with one-fourth vesting at the end of each calendar quarter following the grant date, subject to Bradbury's continued service through each vesting date.